News
HCM
14.96
+0.47%
0.07
Weekly Report: what happened at HCM last week (0202-0206)?
Weekly Report · 1d ago
HUTCHMED (China) Ltd. to Announce Final Results
Reuters · 4d ago
HUTCHMED (China) Ltd. kündigt Veröffentlichung der finalen Geschäftszahlen an
Reuters · 4d ago
HUTCHMED to Announce 2025 Final Results
Barchart · 5d ago
Weekly Report: what happened at HCM last week (0126-0130)?
Weekly Report · 02/02 10:06
BOCOM International Holdings Company Sticks to Their Buy Rating for HUTCHMED (China) (HCM)
TipRanks · 01/29 07:38
Weekly Report: what happened at HCM last week (0119-0123)?
Weekly Report · 01/26 10:06
Bank of America Securities Keeps Their Buy Rating on HUTCHMED (HCM)
TipRanks · 01/22 11:26
Weekly Report: what happened at HCM last week (0112-0116)?
Weekly Report · 01/19 10:11
Hutchmed reports publication of SACHI results in The Lancet
TipRanks · 01/14 10:35
Reported Earlier, HUTCHMED Reports Phase III SACHI Trial Published In The Lancet Demonstrating Improved PFS With Savolitinib Plus Osimertinib Versus Chemotherapy
Benzinga · 01/14 07:19
HUTCHMED Reports Phase III SACHI Trial Success for Savolitinib and Osimertinib in Advanced NSCLC
Reuters · 01/14 04:00
HUTCHMED Highlights Publication of Phase III SACHI Results in The Lancet
Barchart · 01/13 22:00
Weekly Report: what happened at HCM last week (0105-0109)?
Weekly Report · 01/12 10:11
Weekly Buzz: ScinoPharm Gets FDA Nod; GNLX's Olvi-Vec Shows Promise; GLUE's MRT-8102 Advances
NASDAQ · 01/09 12:53
Wall Street Analysts Predict a 55.93% Upside in HUTCHMED (HCM): Here's What You Should Know
NASDAQ · 01/07 14:55
Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026
Benzinga · 01/07 14:17
HUTCHMED's ESLIM-02 Trial Of Sovleplenib In Warm Autoimmune Hemolytic Anemia Meets Key Goal
NASDAQ · 01/07 09:01
Reported Earlier, HUTCHMED Announces Phase III ESLIM-02 Trial Success For Sovleplenib Expanding Immunology And Hematology Pipeline
Benzinga · 01/07 06:45
HUTCHMED's Sovleplenib Reaches Phase III Goal In Warm Autoimmune Hemolytic Anemia Trial In China
NASDAQ · 01/07 00:53
More
Webull provides a variety of real-time HCM stock news. You can receive the latest news about Hutchmed (China) Limited through multiple platforms. This information may help you make smarter investment decisions.
About HCM
HUTCHMED (China) Ltd is an investment holding company principally engaged in the manufacture and sale of pharmaceuticals. The Company operates its business through two segments. Oncology Immunology segment is engaged in the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Among it, research and development (R&D) includes research and development activities covering drug discovery, development, manufacturing and regulatory functions, out-licensing of in-house developed drugs, as well as administrative activities to support research and development operations, marketed products comprises the invoiced sales, marketing, manufacture and distribution of drugs developed from research and development activities. Other Ventures segment is engaged in the other commercial businesses which include the sales, marketing, manufacture and distribution of other prescription drugs and healthcare products.